Payment overview · 2025
General Payments
$540.31
39 reported records · 9 companies
Healthcare provider profile · identity verified
Jason S. Box, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LEAKESVILLE, MS · NPI 1851448906
Verified facts
What the public records show
CMS Open Payments records show Jason S. Box, CRNP received $540.31 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $244.65 | 45.3% | 24 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $145.07 | 26.9% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.51 | 6.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.44 | 4.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.09 | 4.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.75 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.89 | 3.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.33 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.58 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $540.31 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $168.07 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $145.07 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.92 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.57 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $2.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $2.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 525 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 57 |
| Potassium Chloride | Potassium Chloride | 271 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 65 |
| Meloxicam | Meloxicam | 248 | 64 |
| Lisinopril | Lisinopril | 245 | 62 |
| Losartan Potassium | Losartan Potassium | 242 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 54 |
| Metformin Hcl | Metformin Hcl | 230 | 52 |
| Tramadol Hcl | Tramadol Hcl | 230 | 51 |
| Trazodone Hcl | Trazodone Hcl | 219 | 54 |
| Omeprazole | Omeprazole | 210 | 50 |
| Famotidine | Famotidine | 209 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 39 |
| Farxiga | Dapagliflozin Propanediol | 196 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 33 |
| Carvedilol | Carvedilol | 181 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 60 |
| Furosemide | Furosemide | 160 | 48 |
| Montelukast Sodium | Montelukast Sodium | 159 | 34 |
| Pregabalin | Pregabalin | 153 | 26 |
| Buspirone Hcl | Buspirone Hcl | 151 | 29 |
| Sucralfate | Sucralfate | 149 | 33 |
| Allopurinol | Allopurinol | 143 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 30 |
| Prednisone | Prednisone | 138 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 27 |
| Torsemide | Torsemide | 109 | 33 |
| Eliquis | Apixaban | 106 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 41 |
| Ozempic | Semaglutide | 97 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 28 |
| Ibuprofen | Ibuprofen | 83 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 22 |
| Donepezil Hcl | Donepezil Hcl | 81 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 18 |
| Synthroid | Levothyroxine Sodium | 69 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 66 | 22 |
| Mounjaro | Tirzepatide | 62 | 12 |
| Spironolactone | Spironolactone | 62 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 13 |
| Estradiol | Estradiol | 60 | 13 |
| Ondansetron Odt | Ondansetron | 60 | 24 |
| Simvastatin | Simvastatin | 58 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 15 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 33 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 15 |
| Glimepiride | Glimepiride | 45 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 16 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 33 |
| Lorazepam | Lorazepam | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 13 |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Cefdinir | Cefdinir | 35 | 29 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 17 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Linzess | Linaclotide | 29 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Minoxidil | Minoxidil | 28 | suppressed |
| Nystatin | Nystatin | 28 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Baclofen | Baclofen | 26 | 11 |
| Methocarbamol | Methocarbamol | 26 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 14 |
| Acebutolol Hcl | Acebutolol Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | 11 |
| Lacosamide | Lacosamide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $540.31 · 39 records | ABBVIE INC. | BREZTRI, CAPLYTA, CREON, FANAPT, FREESTYLE LIBRE, Kerendia, LINZESS, Omnipod, Ozempic, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error